Skip to main content
Springer logoLink to Springer
. 2019 Mar 11;79(5):585. doi: 10.1007/s40265-019-01088-y

Correction to: Fremanezumab: First Global Approval

Sheridan M Hoy 1,
PMCID: PMC6439160  PMID: 30859411

Correction to: Drugs (2018) 78:1829–1834 10.1007/s40265-018-1004-5

The article Fremanezumab: First Global Approval, written by Sheridan M. Hoy, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1829–1834 Teva Pharmaceuticals requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Teva Pharmaceuticals. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been updated.


Articles from Drugs are provided here courtesy of Springer

RESOURCES